GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (NYSE:BMY) » Definitions » 3-Year Share Buyback Ratio

BMY (Bristol-Myers Squibb Co) 3-Year Share Buyback Ratio : 2.00% (As of Mar. 2025)


View and export this data going back to 1952. Start your Free Trial

What is Bristol-Myers Squibb Co 3-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Bristol-Myers Squibb Co's current 3-Year Share Buyback Ratio was 2.00%.

The historical rank and industry rank for Bristol-Myers Squibb Co's 3-Year Share Buyback Ratio or its related term are showing as below:

BMY' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -11   Med: 0.6   Max: 5.2
Current: 2

During the past 13 years, Bristol-Myers Squibb Co's highest 3-Year Share Buyback Ratio was 5.20%. The lowest was -11.00%. And the median was 0.60%.

BMY's 3-Year Share Buyback Ratio is ranked better than
96.01% of 677 companies
in the Drug Manufacturers industry
Industry Median: -2.1 vs BMY: 2.00

Competitive Comparison of Bristol-Myers Squibb Co's 3-Year Share Buyback Ratio

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bristol-Myers Squibb Co's 3-Year Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's 3-Year Share Buyback Ratio falls into.


;
;

Bristol-Myers Squibb Co 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.


Bristol-Myers Squibb Co (NYSE:BMY) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Bristol-Myers Squibb Co 3-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's 3-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Bristol-Myers Squibb Co Business Description

Address
Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Executives
Samit Hirawat officer: Chief Medical Offr., Drug Dev. BRISTOL-MYERS SQIUBB COMPANY, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Christopher S. Boerner officer: EVP, Chief Commercial Officer 21823 30TH DRIVE S, BOTHELL WA 98021
Samuels Theodore R. Ii director 1990 E. GRAND AVE., EL SEGUNDO CA 90245
Cari Gallman officer: EVP, Corporate Affairs BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Ann Powell Judge officer: SVP, Human Resources BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Robert M Plenge officer: EVP, Chief Research Officer C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Rupert Vessey officer: Pres., Research & Early Dev. C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Adam Lenkowsky officer: EVP, Chief Commercial Officer BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Giovanni Caforio officer: EVP & Chief Commercial Officer BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
David V Elkins officer: EVP, Chief Financial Officer C/O BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Deepak Bhatt director BRISTOL MYERS SQUIBB, 430 E. 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Sandra Leung officer: Vice President and Secretary C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Sharon Greenlees officer: SVP & Controller BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Karin Shanahan officer: EVP, Glob. Prod. Dev. & Supply BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Gregory Scott Meyers officer: EVP, Chief Digital & Tech Off. BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543